Abstract
The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.
Original language | English |
---|---|
Pages (from-to) | 366-367 |
Number of pages | 2 |
Journal | British Journal of Diabetes and Vascular Disease |
Volume | 3 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 Sept 2003 |
Keywords
- EMEA
- NICE
- Pioglitazone
- Rosiglitazone
- Thiazolidinediones